The accumulation of unfolded or misfolded proteins in the endoplasmic reticulum (ER) causes ER stress and activates the unfolded protein response (UPR). As an adaptive cellular response to hostile microenvironments, such as hypoxia, nutrient deprivation, oxidative stress, and chemotherapeutic drugs, the UPR is activated in diverse cancer types and functions as a dynamic tumour promoter in cancer development; this role of the UPR indicates that regulation of the UPR can be utilized as a target for tumour treatment. T-cell exhaustion mainly refers to effector T cells losing their effector functions and expressing inhibitory receptors, leading to tumour immune evasion and the loss of tumour control. Emerging evidence suggests that the UPR plays a crucial role in T-cell exhaustion, immune evasion, and resistance to immunotherapy. In this review, we summarize the molecular basis of UPR activation, the effect of the UPR on immune evasion, the emerging mechanisms of the UPR in chemotherapy and immunotherapy resistance, and agents that target the UPR for tumour therapeutics. An understanding of the role of the UPR in immune evasion and therapeutic resistance will be helpful to identify new therapeutic modalities for cancer treatment.
Background: Tumour-infiltrating lymphocytes (TILs), including T and B cells, have been demonstrated to be associated with tumour progression. However, the different subpopulations of TILs and their roles in breast cancer remain poorly understood. Large-scale analysis using multiomics data could uncover potential mechanisms and provide promising biomarkers for predicting immunotherapy response. Methods: Single-cell transcriptome data for breast cancer samples were analysed to identify unique TIL subsets. Based on the expression profiles of marker genes in these subsets, a TIL-related prognostic model was developed by univariate and multivariate Cox analyses and LASSO regression for the TCGA training cohort containing 1089 breast cancer patients. Multiplex immunohistochemistry was used to confirm the presence of TIL subsets in breast cancer samples. The model was validated with a large-scale transcriptomic dataset for 3619 breast cancer patients, including the METABRIC cohort, six chemotherapy transcriptomic cohorts, and two immunotherapy transcriptomic cohorts. Results: We identified two TIL subsets with high expression of CD103 and LAG3 (CD103+LAG3+), including a CD8+ T-cell subset and a B-cell subset. Based on the expression profiles of marker genes in these two subpopulations, we further developed a CD103+LAG3+ TIL-related prognostic model (CLTRP) based on CXCL13 and BIRC3 genes for predicting the prognosis of breast cancer patients. CLTRP-low patients had a better prognosis than CLTRP-high patients. The comprehensive results showed that a low CLTRP score was associated with a high TP53 mutation rate, high infiltration of CD8 T cells, helper T cells, and CD4 T cells, high sensitivity to chemotherapeutic drugs, and a good response to immunotherapy. In contrast, a high CLTRP score was correlated with a low TP53 mutation rate, high infiltration of M0 and M2 macrophages, low sensitivity to chemotherapeutic drugs, and a poor response to immunotherapy. Conclusions: Our present study showed that the CLTRP score is a promising biomarker for distinguishing prognosis, drug sensitivity, molecular and immune characteristics, and immunotherapy outcomes in breast cancer patients. The CLTRP could serve as a valuable tool for clinical decision making regarding immunotherapy.
Immune checkpoint therapy (ICT) is among the widely used treatments for breast cancer (BC), but most patients do not respond to ICT and the availability of the predictive biomarkers is limited. Emerging evidence indicates that tissue-resident macrophages (RTMs) inhibit BC progression, suggesting that their presence may predict immunotherapy response. A single-cell RNA-sequencing analysis of BC samples was performed to identify five RTM clusters with a mixed phenotype of M1-M2 macrophages. The comprehensive results showed that a high score of each RTM cluster was associated with a high infiltration of CD8+ T cells, M1 macrophages, and dendritic cells, and improved overall survival. In addition, a low score of each RTM cluster was associated with a high infiltration of M0 macrophages, naïve B cells and Tregs, and poor overall survival. Gene signatures from each RTM cluster were significantly enriched in responders compared with nonresponders. Each RTM cluster expression was significantly higher in responders than in nonresponders. The analyses of bulk RNA-seq datasets of BC samples led to identification and validation of a gene expression signature, named RTM.Sig, which contained the related genes of RTM clusters for predicting response to immunotherapy. This study highlights RTM.Sig could provide a valuable tool for clinical decisions in administering ICT.
1 July 2026 in International Journal of Women's Health
Purpose: Understanding which immune cell populations are linked to immunotherapy efficacy is essential for improving treatment stratification in breast cancer. This study aimed to identify immune-relevant cellular subsets from single-cell RNA sequencing (scRNA-seq) data and to develop a prognostic model based on genes characteristic of the relevant population. Methods: scRNA-seq data from breast cancer patients treated with immune checkpoint blockade were reanalyzed to identify cell subsets associated with therapeutic response. The existence of the key subset in tumor tissues was validated by multiplex immunohistochemistry. Marker genes from this subset were then used to construct a prognostic model through Cox regression and least absolute shrinkage and selection operator (LASSO) analysis. The model was further evaluated in two independent GEO cohorts, GSE177043 and GSE169246. Results: A tumor-infiltrating dendritic cell subset defined by CD1c and CLEC10A co-expression was enriched in tumors from responders. Based on the transcriptional signature of this population, we established a tumor-infiltrating dendritic cell-related prognostic model (TRPM). Patients with low TRPM scores had superior survival compared with those with high scores. In addition, lower TRPM scores were associated with a reduced TP53 mutation frequency, increased infiltration of anti-tumor immune cells, including M1 macrophages, plasma cells, CD8+ T cells, and CD4+ T cells, a more immune-active tumor microenvironment, greater predicted drug sensitivity, and improved benefit from immunotherapy. By contrast, higher TRPM scores were linked to a higher TP53 mutation rate, enrichment of M2 macrophages, an immunosuppressive phenotype, decreased drug sensitivity, and poorer predicted response to immunotherapy. In the external immunotherapy cohorts, the model showed good predictive performance, with AUC values of 0.73 in GSE177043 and 0.85 in GSE169246. Conclusion: TRPM may serve as a useful biomarker for stratifying breast cancer patients according to prognosis and likely treatment benefit. This model could support individualized therapeutic decision-making, although prospective clinical validation remains necessary.
About Me
He is a oncologist in the Center for Molecular Medicine, Xiangya Hospital, Central South University.
He is a oncologist in the Center for Molecular Medicine, Xiangya Hospital, Central South University.